Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen

Journal of Experimental Medicine

Volumn 202, Issue 10, 2005, Pages 1375-1386

  Knoechel, Birgit ^a   Lohr, Jens ^a   Kahn, Estelle ^a   Bluestone, Jeffrey A ^a   Abbas, Abul K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GROWTH FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CELL FUNCTION; CELL POPULATION; DISEASE COURSE; EFFECTOR CELL; FEMALE; GRAFT VERSUS HOST REACTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; IMMUNITY, CELLULAR; INTERLEUKIN-2; KINETICS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 27944455288     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20050855     Document Type: Article

References (59)

1. Tanchot, C., D.L. Barber, L. Chiodetti, and R.H. Schwartz. 2001. Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation. J. Immunol. 167:2030-2039.
2. Jameson, S.C. 2002. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2:547-556.
3. Walker, L.S., and A.K. Abbas. 2002. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:11-19.
4. Grossman, Z., B. Min, M. Meier-Schellersheim, and W.E. Paul. 2004. Concomitant regulation of T-cell activation and homeostasis. Nat. Rev. Immunol. 4:387-395.
5. Goldrath, A.W. 2002. Maintaining the status quo: T-cell homeostasis. Microbes Infect. 4:539-545.
6. Deeg, H.J., and R. Storb. 1984. Graft-versus-host disease: pathophysiological and clinical aspects. Annu. Rev. Med. 35:11-24.
7. Klingebiel, T., and P.G. Schlegel. 1998. GVHD: overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant. 21:S45-S49.
8. Arkwright, P.D., M. Abinun, and A.J. Cant. 2002. Autoimmunity in human primary immunodeficiency diseases. Blood. 99:2694-2702.
9. Etzioni, A. 2003. Immune deficiency and autoimmunity. Autoimmun. Rev. 2:364-369.
10. King, C., A. Ilic, K. Koelsch, and N. Sarvetnick. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 117:265-277.
11. Maloy, K.J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816-822.
12. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
13. Shevach, E.M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400.
14. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199:1401-1408.
15. Bluestone, J.A., and A.K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253-257.
16. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492.
17. Kovacs, J.A., S. Vogel, J.M. Albert, J. Falloon, R.T. Davey Jr., R.E. Walker, M.A. Polis, K. Spooner, J.A. Metcalf, M. Baseler, et al. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350-1356.
18. Bruner, R.J., and S.S. Farag. 2003. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin. Oncol. 30:509-519.
19. Jacobsohn, D.A., and G.B. Vogelsang. 2004. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr. Pharm. Des. 10:1195-1205.
20. Gillis, S., and K.A. Smith. 1977. Long term culture of tumour-specific cytotoxic T cells. Nature. 268:154-156.
21. Cousens, L.P., J.S. Orange, and C.A. Biron. 1995. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J. Immunol. 155:5690-5699.
22. Malek, T.R., A. Yu, V. Vincek, P. Scibelli, and L. Kong. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 17:167-178.
23. Lenardo, M.J. 1991. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 353:858-861.
24. Refaeli, Y., L. Van Parijs, C.A. London, J. Tschopp, and A.K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 8:615-623.
25. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A.C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:253-261.
26. Kundig, T.M., H. Schorle, M.F. Bachmann, H. Hengartner, R.M. Zinkernagel, and I. Horak. 1993. Immune responses in interleukin-2-deficient mice. Science. 262:1059-1061.
27. Suzuki, H., T.M. Kundig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. Schmits, J.J. Simard, P.S. Ohashi, H. Griesser, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 268:1472-1476.
28. Willerford, D.M., J. Chen, J.A. Ferry, L. Davidson, A. Ma, and F.W. Alt. 1995. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 3:521-530.
29. Lohr, J., B. Knoechel, E.C. Kahn, and A.K. Abbas. 2004. Role of B7 in T cell tolerance. J. Immunol. 173:5028-5035.
30. Ferrara, J.L., and H.J. Deeg. 1991. Graft-versus-host disease. N. Engl. J. Med. 324:667-674.
31. Reddy, P. 2003. Pathophysiology of acute graft-versus-host disease. Hematol. Oncol. 21:149-161.
32. Prlic, M., B.R. Blazar, A. Khoruts, T. Zell, and S.C. Jameson. 2001. Homeostatic expansion occurs independently of costimulatory signals. J. Immunol. 167:5664-5668.
33. Gudmundsdottir, H., and L.A. Turka. 2001. A closer look at homeostatic proliferation of CD4+ T cells: costimulatory requirements and role in memory formation. J. Immunol. 167:3699-3707.
34. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
35. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
36. + regulatory T cells in vivo. J. Exp. Med. 198:249-258.
37. Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. J. Immunol. 172:5973-5979.
38. Malek, T.R., and A.L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4:665-674.
39. Granucci, F., C. Vizzardelli, N. Pavelka, S. Feau, M. Persico, E. Virzi, M. Rescigno, G. Moro, and P. Ricciardi-Castagnoli. 2001. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2:882-888.
40. Anderson, B.E., J.M. McNiff, C. Matte, I. Athanasiadis, W.D. Shlomchik, and M.J. Shlomchik. 2004. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 104:1565-1573.
41. + regulatory T cell function. J. Exp. Med. 196:851-857.
42. McHugh, R.S., and E.M. Shevach. 2002. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol. 168:5979-5983.
43. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries, and M.G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
44. Weiner, H.L. 2001. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182:207-214.
45. Bacchetta, R., C. Sartirana, M.K. Levings, C. Bordignon, S. Narula, and M.G. Roncarolo. 2002. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur. J. Immunol. 32:2237-2245.
46. + T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195:603-616.
47. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198:1875-1886.
48. Blattman, J.N., J.M. Grayson, E.J. Wherry, S.M. Kaech, K.A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-547.
49. Nelson, B.H. 2002. Interleukin-2 signaling and the maintenance of self-tolerance. Curr. Dir. Autoimmun. 5:92-112.
50. Almeida, A.R., N. Legrand, M. Papiernik, and A.A. Freitas. 2002. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J. Immunol. 169:4850-4860.
51. Curotto de Lafaille, M.A., A.C. Lino, N. Kutchukhidze, and J.J. Lafaille. 2004. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J. Immunol. 173:7259-7268.
52. Klein, L., K. Khazaie, and H. von Boehmer. 2003. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl. Acad. Sci. USA. 100:8886-8891.
53. Nussenblatt, R.B., D.J. Thompson, Z. Li, J.S. Peterson, R.R. Robinson, R.S. Shames, S. Nagarajan, M.T. Tang, M. Mailman, G. Velez, et al. 2003. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 21:283-293.
54. Belanger, C., H. Esperou-Bourdeau, P. Bordigoni, J.P. Jouet, G. Souillet, N. Milpied, X. Troussard, M. Kuentz, P. Herve, J. Reiffers, et al. 1993. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant. 11:293-297.
55. Anasetti, C., J.A. Hansen, T.A. Waldmann, F.R. Appelbaum, J. Davis, H.J. Deeg, K. Doney, P.J. Martin, R. Nash, R. Storb, et al. 1994. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 84:1320-1327.
56. Przepiorka, D., N.A. Kernan, C. Ippoliti, E.B. Papadopoulos, S. Giralt, I. Khouri, J.G. Lu, J. Gajewski, A. Durett, K. Cleary, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 95:83-89.
57. Lee, S.J., D. Zahrieh, E. Agura, M.L. MacMillan, R.T. Maziarz, P.L. McCarthy Jr., V.T. Ho, C. Cutler, E.P. Alyea, J.H. Antin, and R.J. Soiffer. 2004. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 104:1559-1564.
58. Khattri, R., T. Cox, S.A. Yasayko, and F. Ramsdell. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4:337-342.
59. Grogan, J.L., M. Mohrs, B. Harmon, D.A. Lacy, J.W. Sedat, and R.M. Locksley. 2001. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity. 14:205-215.